Navigation Links
Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
Date:5/11/2009

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming Bank of America and Merrill Lynch Conference in New York City. Mr. Patterson's presentation is scheduled to begin on Wednesday, May 13th at 4:00 p.m. EDT.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date
2. Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
3. Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
4. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
5. Amicus Therapeutics Announces Change to Board of Directors
6. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
7. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
8. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
9. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
10. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
11. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Chef Jodi Abel has returned from her three-week ... cities, she gained a number of delicious recipes and new techniques to share with ... Africa’s Western Cape province. It is internationally renowned for its incredible wine farms, ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/23/2017)... YORK , Feb. 23, 2017 ... digital health company, and Digital Noema Telehealth ... remote patient monitoring, announce they are partnering to ... DN Telehealth maximizes collaboration compatibility for its ... beyond a physical clinical setting to include fully ...
(Date:2/23/2017)... it seems everyone has a chance to express their personalities. ... and dynamic community unlike any other. The businesses that succeed ... With their newest salon in Dunwoody ... that tradition with a unique, fresh approach to head lice ... newest of 13 nationwide locations, each of them well-situated in ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):